NF2 and schwannoma: GSK2126458, Panobinostat, and CUDC-907 were evaluated in a genetically-engineered mouse (GEM) model of NF2, PostnCre; Nf2floxflox, that develops schwannoma of the dorsal root ganglia (DRG) and cranial nerves [19].